ELI-002 7P Misses Primary End Point in Phase 2 AMPLIFY-7P PDAC Study

Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and ...

100% confirmed complete radiographic and complete metabolic responses in three patients who progressed on ELI-002 7P treatment during the Phase 2 AMPLIFY-7P study and received nivolumab-based subsequent therapyComplete responses (“CRs”) are rarely (0-8%) observed in metastatic pancreatic cancer in published…

ELI-002 7P Misses Primary End Point in Phase 2 AMPLIFY-7P PDAC Study

The phase 2 AMPLIFY-7P trial did not meet its primary DFS end point, though post-hoc analyses identified a benefit in R0-resected patients with mKRAS PDAC.